Protected PCI

Patient Identification

Which Patients May Benefit from Protected PCI?

Impella® heart pumps may provide safe and effective hemodynamic support in elective and urgent high-risk PCI for a broad range of patients with complex coronary artery disease, hemodynamic compromise and comorbidities.

    Patients benefit from this minimally invasive option that may:

    • Enable more complete revascularization1
    • Reduce symptoms and class of heart failure2 and improve LVEF1
    • Significantly reduce the overall incidence of post-procedural acute kidney injury (AKI)5
    • Reduce number of days in the hospital3,4
    • Significantly reduce post-discharge MACCE events (composite of death/stroke/MI/repeat revascularization)6

    Surgical Turndown is Common and Associated with Higher Mortality

    Protected PCI may be an option when surgery is not. Consider Protected PCI for patients who are considered too high-risk and therefore turned down for surgery, and for patients who decline surgical treatment.

    Underdiagnosed & Undertreated

    Many patients with severe, symptomatic CAD remain untreated or undertreated due to comorbidities, increased risk of AKI or hemodynamic compromise.

    Resources from the Education Library

    Video describing Protected PCI for Superior Long-Term Outcomes from SCAI 2021

    Protected PCI for Superior Long-Term Outcomes

    Gregg Stone, MD, and Duane Pinto, MD, host this panel discussion from SCAI 2021 of Protected PCI and diagnosis and treatment of high-risk and complex coronary disease.


    High-Risk PCI with Impella Support and Atherectomy

    Thom Dahle, MD, presents the case of an 84-year-old with a history of CAD with prior stenting of the circumflex. In this case, the patient is his father.

    Clinical Evidence

    Read extensive data, including RCT findings and a published literature review of 3,301 patients, that supports Impella® safety and efficacy.


    1. Burzotta, F., et al. (2019). J Interv Cardiol, 2019(5):1-10.

    2. O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.

    3. Gregory, D., et al. (2013). Am Health Drug Benefits, 6(2), 88-99.

    4. Maini, B., et al. (2014). Expert Rev Pharmacoecon Outcomes Res, 14(3), 403-416.

    5. Flaherty, M.P., et al. (2017). Circ Res, 120(4), 692-700.
    6. Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228.